Please Wait...

Bioclinica Provides Risk-Based Monitoring Solution in Japan

EPS to Run Clinical Studies Using COMPASS

January 25, 2016

Bioclinica®, Inc., a specialty clinical trials technology and services provider, today announced Japanese CRO, EPS Corporation (EPS), has selected Bioclinica COMPASS technology and professional services as its risk-based monitoring (RBM) solution for clinical trials in Japan.

 Download a print version - Japanese
Adobe Reader Required

"We are thrilled that EPS, with a reputation as Japan's most progressive CRO, has chosen Bioclinica to pioneer RBM," said Bioclinica Senior Vice President of Product Development and Technology Andrew Masters. "We provide a complete integrated software solution aimed at satisfying risk-averse CROs and sponsors. This includes giving EPS the ability to track Key Risk Indicators with related tasks and actions across their entire study portfolio. Centralized monitoring with COMPASS is a better, more cost-effective way to monitor clinical trials, and aims to improve site performance and overall study quality."

"EPS has been eager to implement effective RBM services consistent with MHLW/PMDA, FDA and EMA initiatives – one capable of handling our volume and diversity in studies," said EPS President and Representative Director Hisashi Tanaka. "From our comprehensive survey of commercially available RBM technologies, we concluded that our RBM services with Bioclinica COMPASS and comprehensive technology and professional services would best meet the intent of RBM, while addressing all three factors critical for successful RBM services – people, process and technology – together in an RBM SaaS solution with exceptional data integration capabilities."

Bioclinica offers a feature-rich RBM solution with a library of 44 standard KRIs and an ability to add additional custom KRIs. Tracking and visualization at the study and site level, combined with robust alert and action recommendations, stood out over competing systems in extensive evaluation and sandbox testing, according to Tanaka. "When we looked at configurability, ease of deployment, ability to connect to existing eClinical systems and overall flexibility of the solution to meet our needs, COMPASS came out ahead as the RBM enterprise solution for us."

Masters explained, "Data integration is the backbone of successful RBM analytics. COMPASS was specifically designed to process operational and patient data from EDC, CTMS, RTSM and other source systems with little configuration, providing users the utmost confidence in our RBM analytics."

"We expect our comprehensive RBM solution to make a marked and tangible difference in the ability of EPS to view and manage KRIs," Masters added. COMPASS provides study teams with early visibility into site and patient trends for improved data quality and oversight of trials, reducing costs through centralized, technology-enabled monitoring.

Study managers, monitors and other EPS team members are participating in a comprehensive training program. "We want to ensure our customers become as adept at using COMPASS as own team," Masters said. "Bioclinica is shifting the paradigm to technology enablement, making CROs autonomous."

Implementation of Bioclinica COMPASS and associated RBM professional services is underway with the technology rolling out on live studies in coming months. "EPS is looking forward to working with Bioclinica in this technologically innovative RBM era to contribute to pharmaceutical product development," Tanaka said.

Find out more about Bioclinica and its eHealth solutions at www.bioclinica.com, and on Twitter at http://twitter.com/bioclinica.

About EPS Corporation
EPS is a 100 percent subsidiary company of EPS Holdings Inc. (TYO: 4282) and part of a large organization within the EPS Group. EPS is one of the leading companies of CRO (Contract Research Organization) services providing full support – from the planning of clinical trials to post-marketing surveillance – for the development pursuits of pharmaceutical companies, in Japan. 

Learn more at http://www.eps-holdings.co.jp/en/about/network.html and http://www.eps.co.jp/.

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's cloud-based offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers a global network of research sites and patient recruitment services to provide committed, detail-focused service through all stages of drug development. The company's thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.

Learn more about Bioclinica and our Clinical Adjudication and other offerings at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Medical Imaging of Non-Alcoholic Fatty Liver Diseases in Clinical Trials – Where Do We Stand?… https://t.co/zJJlrbyMAq
Bioclinica (21 hours ago)
Bioclinica's Electronic Data Capture #EDC has been used in thousands of clinical studies worldwide. Why? Our single… https://t.co/9IHk8a9NIZ
Bioclinica (4 days ago)
Is Your Study Supply Chain Management Solution Increasing the Risk of Stock Out Situations? https://t.co/zGMRSwAunZ… https://t.co/4BiypLB06k
Bioclinica (5 days ago)
Here are the five questions to ask your IRT vendor. https://t.co/JSc0RwKOyp #clinicaltrials #irt https://t.co/TbMgM8ull8
Bioclinica (6 days ago)
Over 25 years of experience, we offer world-renowned scientific expertise, regulatory leadership, and integrated te… https://t.co/owAFAqIHT7
Bioclinica (1 week ago)
Your trial needs Bioclinica experts who can see more deeply into essential imaging data. We offer expertise in… https://t.co/mNdCRkZYeI
Bioclinica (2 weeks ago)

Latest Blogs:

Medical Imaging of Non-Alcoholic Fatty Liver Diseases in Clinical Trials
EDC Provider Selection
Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box